Federal Register / Vol. 83, No. 31 / Wednesday, February 14, 2018 / Notices 6563 Wireless Telecommunications Bureau Signed: DEPARTMENT OF HEALTH AND and Wireline Competition Bureau (the Dayna C. Brown, HUMAN SERVICES Bureaus) may implement, and (3) certify Secretary and Clerk of the Commission. Centers for Disease Control and its challenge. The USAC system will [FR Doc. 2018–03166 Filed 2–12–18; 4:15 pm] validate a challenger’s evidence using Prevention BILLING CODE 6715–01–P an automated challenge validation [CDC–2018–0004; NIOSH–233–B] process. Once all valid challenges have been identified, a challenged party that NIOSH List of Antineoplastic and Other chooses to respond to any valid FEDERAL RESERVE SYSTEM Hazardous Drugs in Healthcare challenge(s) may submit additional data Settings: Proposed Additions to the via the online USAC portal during the Change in Bank Control Notices; NIOSH Hazardous Drug List 2018 established response window. A Acquisitions of Shares of a Bank or AGENCY: Centers for Disease Control and challenged party may submit technical Bank Holding Company information that is probative regarding Prevention, HHS. ACTION: Notice of draft document the validity of a challenger’s speed tests, The notificants listed below have available for public comment. including speed test data and other applied under the Change in Bank device-specific data collected from Control Act (12 U.S.C. 1817(j)) and transmitter monitoring software or, SUMMARY: The National Institute for § 225.41 of the Board’s Regulation Y (12 alternatively, may submit its own speed Occupational Safety and Health test data that conforms to the same CFR 225.41) to acquire shares of a bank (NIOSH) of the Centers for Disease standards and requirements specified by or bank holding company. The factors Control and Prevention (CDC) the Commission and the Bureaus for that are considered in acting on the announces the availability for public challengers. notices are set forth in paragraph 7 of comment on the drugs proposed for the Act (12 U.S.C. 1817(j)(7)). placement on the NIOSH List of In conjunction with the qualified 4G The notices are available for Antineoplastic and Other Hazardous LTE data separately collected pursuant Drugs in Healthcare Settings, 2018 immediate inspection at the Federal to OMB 3060–1242 that will be used to (List), as well as the NIOSH Policy and Reserve Bank indicated. The notices create the map of areas presumptively Procedures for Developing the NIOSH also will be available for inspection at eligible for MF–II support, the List of Antineoplastic and Other information collected under this MF–II the offices of the Board of Governors. Hazardous Drugs in Healthcare Settings. challenge process collection will enable Interested persons may express their DATES: Comments must be received by the Commission to efficiently resolve views in writing to the Reserve Bank April 16, 2018. disputes concerning the eligibility or indicated for that notice or to the offices ineligibility of an area initially deemed of the Board of Governors. Comments ADDRESSES: Comments may be ineligible for MF–II support and must be received not later than March submitted, identified by docket numbers CDC–2018–0004 and NIOSH–233–B, by establish the final map of areas eligible 7, 2018. for such support, thereby furthering the either of the following two methods: A. Federal Reserve Bank of Atlanta • Commission’s goal of targeting MF–II Federal eRulemaking Portal: support to areas that lack adequate (Kathryn Haney, Director of www.regulations.gov. Follow the mobile voice and broadband coverage Applications) 1000 Peachtree Street NE, instructions for submitting comments. • absent subsidies through a transparent Atlanta, Georgia 30309. Comments can Mail: NIOSH Docket Office, Robert process. also be sent electronically to A. Taft Laboratories, MS–C34, 1090 [email protected]: Tusculum Avenue, Cincinnati, OH The Commission received approval 45226–1998. from OMB for the information collection 1. Brandt J. Dufrene, Sr., individually Instructions: All information received requirements contained in OMB 3060– and as trustee for The FSC Trust No. 1, in response to this notice must include 1251 on February 7, 2018. and Brandt J. Dufrene, Jr., individually the agency name and the docket and as the trustee for The FSC Trust No. Federal Communications Commission. numbers (CDC–2018–0004; NIOSH– 2 and the Brandt J. Dufrene, Jr. Trust Marlene H. Dortch, 233–B). All relevant comments received No. 1, all of Metairie, Louisiana; to Secretary, Office of the Secretary. will be posted without change to retain voting shares of First St. Charles [FR Doc. 2018–03000 Filed 2–13–18; 8:45 am] www.regulations.gov, including any Bancshares, Inc., and thereby indirectly personal information provided. BILLING CODE 6712–01–P retain First National Bank USA, both FOR FURTHER INFORMATION CONTACT: Boutte, Louisiana. Barbara MacKenzie, NIOSH, Robert A. Board of Governors of the Federal Reserve Taft Laboratories, 1090 Tusculum FEDERAL ELECTION COMMISSION System, February 9, 2018. Avenue, MS–C26, Cincinnati, OH Ann E. Misback, 45226, telephone (513) 533–8132 (not a Sunshine Act Meeting Secretary of the Board. toll free number), Email: [FR Doc. 2018–03082 Filed 2–13–18; 8:45 am] [email protected]. TIME AND DATE: Thursday, February 15, SUPPLEMENTARY INFORMATION: 2018 at 10:00 a.m. BILLING CODE P I. Public Participation PLACE: 999 E Street NW, Washington, DC (Ninth Floor). Interested parties are invited to participate in this action by submitting STATUS: This Meeting, open to the written views, opinions, public, has been cancelled. recommendation, and/or data. CONTACT PERSON FOR MORE INFORMATION: Comments are invited on any topic Judith Ingram, Press Officer, Telephone: related to the drugs identified in this (202) 694–1220. notice, including those evaluated for daltland on DSKBBV9HB2PROD with NOTICES VerDate Sep<11>2014 22:07 Feb 13, 2018 Jkt 244001 PO 00000 Frm 00057 Fmt 4703 Sfmt 4703 E:\FR\FM\14FEN1.SGM 14FEN1 6564 Federal Register / Vol. 83, No. 31 / Wednesday, February 14, 2018 / Notices placement on the NIOSH List of Other Hazardous Drugs in Healthcare In accordance with the draft Antineoplastic and Other Hazardous Settings, to formalize the methodology hazardous drugs policy and procedures, Drugs in Healthcare Settings, 2018. NIOSH uses to guide the addition of NIOSH uses FDA databases to identify NIOSH also seeks comment on the draft hazardous drugs to the List (see https:// new drug approvals and drugs with new Policy and Procedures for Developing www.cdc.gov/niosh/topics/hazdrug/ safety warnings. the NIOSH List of Antineoplastic and default.html). The draft document Information pertaining to each new Other Hazardous Drugs in Healthcare clarifies and details the purpose of the drug and drugs with new safety Settings, available in the docket for this List, which is to assist employers in warnings is screened to determine action. NIOSH invites comments providing safe and healthful workplaces whether a specific drug is potentially specifically on the following questions by offering a list of drugs that meet the hazardous. Potentially hazardous drugs related to this action: NIOSH definition of a hazardous drug, are those for which the manufacturer 1. Has NIOSH appropriately identified and sets out the procedures used by has provided special handling and categorized the drugs considered for NIOSH to identify such drugs. The draft information intended to protect placement on the NIOSH List of policy and procedures will be finalized workers, or for which available toxicity Antineoplastic and Other Hazardous after consideration of comments to this information suggests that a drug may Drugs in Healthcare Settings, 2018? 6 docket and from peer reviewers. exhibit one of the types of toxicity in the 2. Is information available from FDA According to the draft hazardous or other Federal agencies or in the NIOSH definition of a hazardous drug. drugs policy and procedures, NIOSH Drugs for which insufficient toxicity published, peer-reviewed scientific defines a hazardous drug as a drug that literature about a specific drug or drugs information is available and drugs for is: which the available information identified in this notice that would 1. Approved for use in humans 7 by justify the reconsideration of NIOSH’s suggests no toxic effect or a toxic effect the FDA; 8 and that does not meet the NIOSH definition categorization decision? 2. Not otherwise regulated by the U.S. 3. Does the draft Policy and of a hazardous drug are not proposed for Nuclear Regulatory Commission; 9 and Procedures for Developing the NIOSH placement on the List and are not 3. Either: List of Antineoplastic and Other further considered. Drugs for which a. Accompanied by prescribing special handling information is Hazardous Drugs in Healthcare Settings 10 include a methodology for reviewing information in the ‘‘package insert’’ available are published on the NIOSH toxicity information that is appropriate that includes special handling website and proposed for placement on for this activity? information to protect workers handling the List; these drugs are not further the drug; or evaluated. II. Background b. Exhibits one or more of the Drugs for which the available In September 2004, NIOSH published following types of toxicity in humans, information suggests that the drug NIOSH Alert: Preventing Occupational animal models, or in vitro systems: exhibits one or more toxic effects that Exposures to Antineoplastic and Other Carcinogenicity; teratogenicity or other meet the NIOSH definition of a Hazardous Drugs in Health Care developmental toxicity; reproductive hazardous drug are further evaluated to Settings (Alert).1 The 2004 Alert set out toxicity; organ toxicity at low doses; determine whether the drug should be a general NIOSH policy for the genotoxicity; or structure and toxicity proposed for placement on the List. To identification of hazardous drugs and profile that mimics existing drugs conduct the evaluation of drugs for contained examples of U.S.